FINWIRES · TerminalLIVE
FINWIRES

艾伯维公司已向FDA提交Upadacitinib用于治疗斑秃的申请。

By

-- 艾伯维(AbbVie,股票代码:ABBV)周二宣布,已向美国食品药品监督管理局(FDA)提交了upadacitinib新适应症的申请,用于治疗成人和青少年重度斑秃患者。 该公司表示,此次申请使用了upadacitinib(商品名:Rinvoq)的3期临床试验数据。艾伯维称,该试验达到了主要终点,即在第24周时斑秃严重程度评分≤20。 该公司还补充道,upadacitinib在该试验中的安全性与此前公布的研究结果一致。

Price: $197.37, Change: $-0.03, Percent Change: -0.02%

Related Articles

Australia

Jefferies Adjusts Price Target on Pfizer to $35 From $34, Maintains Buy Rating

Pfizer (PFE) has an average rating of hold and mean price target of $28.90, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $26.60, Change: $-0.20, Percent Change: -0.73%

$PFE
Australia

Market Chatter: Amazon to Sell OpenAI Models as Microsoft Drops Exclusive Rights

Amazon.com (AMZN) plans to make OpenAI's artificial-intelligence models available to its customers after Microsoft (MSFT) relinquished its exclusive rights to resell the ChatGPT maker's products, Bloomberg reported Tuesday, citing Amazon Web Services CEO Matt Garman in a Bloomberg Television interview.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $258.22, Change: $-2.85, Percent Change: -1.09%

$AMZN$MSFT
Mining & Metals

Air Canada Price Target Cut to $25.50 at Stifel Canada

Stifel Canada trimmed its price target on Air Canada (AC.TO) shares to $25.50 from $28.00 while maintaining its buy rating ahead of the company reporting its first-quarter results after market close on April 30.Analyst Daryl Young expects the results to be relatively strong, despite challenges related to winter storms, Cuba fuel crises, Mexico safety disruptions, and the Middle East conflict. "However, the key focus will be the durability of demand and pace of fuel price pass-through heading into the peak Q3 period (traditionally >40% of EBITDA)."Young believes demand has remained resilient. Air Canada is also well-positioned versus smaller Canadian peers given its scale, flexible fleet, and segmented offering, he points out."We expect AC to lower its full-year 2026 guidance alongside Q1/26 results or possibly withdraw it altogether, in favour of quarter-to-quarter guidance pending fuel price stability."Price: $18.30, Change: $-0.22, Percent Change: -1.19%

$AC.TO